NASDAQ:PSTX

Poseida Therapeutics Stock Forecast, Price & News

$9.21

-0.26 (-2.75 %)

(As of 06/14/2021 12:00 AM ET)

Add

Compare

Today's Range

$9.17

▼

$9.72

50-Day Range

$7.96

▼

$9.79

52-Week Range

$7.63

▼

$17.62

Volume200,668 shs

Average Volume312,925 shs

Market Capitalization$572.45 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive PSTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Poseida Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Poseida Therapeutics

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat relapsed/refractory multiple myeloma patients; P-MUC1C-ALLO1, an allogeneic CAR-T product candidate for multiple solid tumor indications; and P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. It is also developing P-OTC-101, a liver-directed gene therapy for the treatment of ornithine transcarbamylase; and P-MMUT-101, a liver-directed gene therapy for the treatment of methylmalonic acidemia. In addition, the company is developing a portfolio of allogeneic dual CAR product candidates. The company was incorporated in 2014 and is headquartered in San Diego, California.

Poseida Therapeutics (NASDAQ:PSTX) Stock Price Up 4.9%
June 10, 2021 | americanbankingnews.com

Poseida Therapeutics (NASDAQ:PSTX) & Adaptive Biotechnologies (NASDAQ:ADPT) Head-To-Head Comparison
June 4, 2021 | americanbankingnews.com

Insider Selling: Poseida Therapeutics, Inc. (NASDAQ:PSTX) CEO Sells 41,194 Shares of Stock
June 4, 2021 | americanbankingnews.com

Poseida Therapeutics (NASDAQ:PSTX) Trading 6% Higher
June 3, 2021 | americanbankingnews.com

Poseida Therapeutics Announces Virtual 2021 Annual Meeting of Stockholders
June 2, 2021 | finance.yahoo.com

Poseida Therapeutics (NASDAQ:PSTX) Trading Down 8.7%
May 24, 2021 | americanbankingnews.com

BTIG Research Initiates Coverage on Poseida Therapeutics (NASDAQ:PSTX)
May 24, 2021 | americanbankingnews.com

Equities Analysts Offer Predictions for Poseida Therapeutics, Inc.'s Q2 2021 Earnings (NASDAQ:PSTX)
May 20, 2021 | americanbankingnews.com

Poseida Therapeutics (NASDAQ:PSTX) & Iovance Biotherapeutics (NASDAQ:IOVA) Head to Head Survey
May 20, 2021 | americanbankingnews.com

Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021
May 11, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PSTX
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.poseida.com
Phone858-779-3100
Employees206
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.24 per share
Price / Book2.17

Profitability

EPS (Most Recent Fiscal Year)($3.61)
Net Income$-129,770,000.00
Net MarginsN/A
Return on Equity-96.07%
Return on Assets-41.70%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares62,155,000
Market Cap$572.45 million
Next Earnings Date8/19/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.69 out of 5 stars

Medical Sector

327th out of 2,100 stocks

Biological Products, Except Diagnostic Industry

42nd out of 198 stocks

3.5 Analyst's Opinion

Consensus Rating
Poseida Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $30.00, Poseida Therapeutics has a forecasted upside of 225.7% from its current price of $9.21.
Amount of Analyst Coverage
Poseida Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.5 Community Rank

Outperform Votes
Poseida Therapeutics has received 9 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Poseida Therapeutics has received 4 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Poseida Therapeutics has received 69.23% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Poseida Therapeutics and other stocks. Vote “Outperform” if you believe PSTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PSTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Poseida Therapeutics does not currently pay a dividend.
Dividend Growth
Poseida Therapeutics does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Poseida Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,658,168.00 in company stock.
Percentage Held by Insiders
Only 19.03% of the stock of Poseida Therapeutics is held by insiders.
Percentage Held by Institutions
46.12% of the stock of Poseida Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Poseida Therapeutics are expected to grow in the coming year, from ($2.56) to ($2.53) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Poseida Therapeutics is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Poseida Therapeutics is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Poseida Therapeutics has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Poseida Therapeutics (NASDAQ:PSTX) Frequently Asked Questions

Is Poseida Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Poseida Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Poseida Therapeutics stock.
View analyst ratings for Poseida Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Poseida Therapeutics?

Wall Street analysts have given Poseida Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Poseida Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Poseida Therapeutics' next earnings date?

Poseida Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 19th 2021.
View our earnings forecast for Poseida Therapeutics.

How were Poseida Therapeutics' earnings last quarter?

Poseida Therapeutics, Inc. (NASDAQ:PSTX) announced its earnings results on Tuesday, May, 11th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.64) by $0.02.
View Poseida Therapeutics' earnings history.

What price target have analysts set for PSTX?

4 analysts have issued 12 month target prices for Poseida Therapeutics' shares. Their forecasts range from $20.00 to $40.00. On average, they expect Poseida Therapeutics' share price to reach $30.00 in the next twelve months. This suggests a possible upside of 225.7% from the stock's current price.
View analysts' price targets for Poseida Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Poseida Therapeutics' key executives?

Poseida Therapeutics' management team includes the following people:

Dr. Eric M. Ostertag, CEO & Director (Age 48, Pay $858.68k)
Mr. Mark J. Gergen, Pres, Chief Bus. Officer & Director (Age 58, Pay $636.49k)
Mr. Harry J. Leonhardt, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 64, Pay $494.54k)
Ms. Johanna M. Mylet CPA, Sr. VP of Fin. (Age 34)
Mr. Kerry D. Ingalls, Chief Operating Officer (Age 59)
Sarah Thailing, Director of Corp. Communications & IR
Ms. Kristin Martin, Chief HR Officer
Dr. Devon J. Shedlock, Sr. VP of R&D
Dr. Matthew A. Spear, Chief Medical Officer (Age 54)
Mr. Jeff Knight, Sr. VP of Portfolio Management & Corp. Operations

Who are some of Poseida Therapeutics' key competitors?

Some companies that are related to Poseida Therapeutics include Kymera Therapeutics (KYMR), bluebird bio (BLUE), Instil Bio (TIL), C4 Therapeutics (CCCC), Immunocore (IMCR), Sangamo Therapeutics (SGMO), Alector (ALEC), ImmunityBio (IBRX), Replimune Group (REPL), Translate Bio (TBIO), REGENXBIO (RGNX), AlloVir (ALVR), Krystal Biotech (KRYS), Cortexyme (CRTX) and Valneva (VALN).
View all of PSTX's competitors.

What other stocks do shareholders of Poseida Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Poseida Therapeutics investors own include Moderna (MRNA), Advanced Micro Devices (AMD), AngloGold Ashanti (AU), Micron Technology (MU), Eaton (ETN), Corning (GLW), OPKO Health (OPK), Overstock.com (OSTK), Sorrento Therapeutics (SRNE) and SSR Mining (SSRM).

When did Poseida Therapeutics IPO?

(PSTX) raised $150 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair acted as the underwriters for the IPO.

What is Poseida Therapeutics' stock symbol?

Poseida Therapeutics trades on the NASDAQ under the ticker symbol "PSTX."

Who are Poseida Therapeutics' major shareholders?

Poseida Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.55%), Millennium Management LLC (2.84%), Schonfeld Strategic Advisors LLC (0.67%), Geode Capital Management LLC (0.65%), JPMorgan Chase & Co. (0.50%) and Advisory Services Network LLC (0.41%). Company insiders that own Poseida Therapeutics stock include Eric Ostertag, Matthew A Spear and Sean Murphy.
View institutional ownership trends for Poseida Therapeutics.

Which institutional investors are selling Poseida Therapeutics stock?

PSTX stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, and Goldman Sachs Group Inc.. Company insiders that have sold Poseida Therapeutics company stock in the last year include Eric Ostertag, and Matthew A Spear.
View insider buying and selling activity for Poseida Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Poseida Therapeutics stock?

PSTX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Schonfeld Strategic Advisors LLC, JPMorgan Chase & Co., Millennium Management LLC, Advisory Services Network LLC, Pura Vida Investments LLC, Geode Capital Management LLC, and Nuveen Asset Management LLC.
View insider buying and selling activity for Poseida Therapeutics or or view top insider-buying stocks.

How do I buy shares of Poseida Therapeutics?

Shares of PSTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Poseida Therapeutics' stock price today?

One share of PSTX stock can currently be purchased for approximately $9.21.

How much money does Poseida Therapeutics make?

Poseida Therapeutics has a market capitalization of $572.45 million. The company earns $-129,770,000.00 in net income (profit) each year or ($3.61) on an earnings per share basis.

How many employees does Poseida Therapeutics have?

Poseida Therapeutics employs 206 workers across the globe.

What is Poseida Therapeutics' official website?

The official website for Poseida Therapeutics is www.poseida.com.

Where are Poseida Therapeutics' headquarters?

Poseida Therapeutics is headquartered at 9390 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121.

How can I contact Poseida Therapeutics?

Poseida Therapeutics' mailing address is 9390 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The company can be reached via phone at 858-779-3100.

This page was last updated on 6/14/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here